In treating schizophrenia, lumateperone exhibited a lower combined SMD of -0.14 (95% CI: −.27 to 0, P = .051, I2 = 49.6%), showing no significant difference from the placebo group, although the P -value approached significance.
← all excerpts
Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis.
1
—
—